IMUX:NASDAQImmunic, Inc. Analysis
Data as of 2026-06-21 - not real-time
$14.20
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Technical outlook: IMUX trades at $14.20, comfortably above its 20‑day, 50‑day and 200‑day moving averages, indicating a bullish price trend. The RSI sits near 58, suggesting momentum remains on the upside, while the MACD histogram is marginally negative, hinting at a possible near‑term pullback. Support sits around $10.87 and resistance near $15.77, with the current price approaching the upper band of its 52‑week range.
Fundamentals and catalysts: The company is still pre‑revenue, reporting negative EPS and sizable cash burn, yet it holds $186 M in cash against modest debt, giving it roughly a two‑year runway. Recent material news includes a late‑breaking poster on Phase 2 CALLIPER trial data for IMU‑838 in progressive MS and the appointment of a new CEO, both of which could act as short‑term catalysts. Analysts’ price targets average $42‑$45, implying >200% upside, while market sentiment is in “Extreme Greed” territory.
Fundamentals and catalysts: The company is still pre‑revenue, reporting negative EPS and sizable cash burn, yet it holds $186 M in cash against modest debt, giving it roughly a two‑year runway. Recent material news includes a late‑breaking poster on Phase 2 CALLIPER trial data for IMU‑838 in progressive MS and the appointment of a new CEO, both of which could act as short‑term catalysts. Analysts’ price targets average $42‑$45, implying >200% upside, while market sentiment is in “Extreme Greed” territory.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near technical resistance at $15.77
- MACD showing slight bearish divergence
- Upcoming presentation of Phase 2 data
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Potential efficacy readout from CALLIPER trial
- Strong cash position relative to low debt
- Analyst consensus upside >200%
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Pipeline of oral immunology therapies targeting high‑need autoimmune diseases
- Undervalued price‑to‑book ratio (~1.3×)
- Strategic leadership change with experienced CEO
Key Metrics & Analysis
Financial Health
P/E Ratio-4.0
ROE-142.91%
ROA-65.18%
Debt/Equity0.28
P/B Ratio1.3
Op. Cash Flow$-81331000
Free Cash Flow$-41392752
Industry P/E24.1
Technical Analysis
TrendBullish
RSI58.4
Support$10.87
Resistance$15.77
MA 20$13.62
MA 50$12.01
MA 200$9.22
MACDBearish
VolumeDecreasing
Fear & Greed Index91.46
Valuation
Target Price$44.67
Upside/Downside214.55%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.67
Volatility79.44%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.